Inspiremd receives reimbursement approval for cguard™ embolic prevention system from the french national authority for health

Tel aviv, israel, oct. 13, 2021 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), a global developer of the cguard™ embolic prevention stent system (eps) device for the treatment of carotid artery disease (cad) and stroke prevention, today announced that its cguard eps stent system has received a positive opinion from the national commission for the evaluation of medical devices and health technologies (cnedimts) of the french national authority for health (has) regarding reimbursement in france, and the cguard eps is being added to the list of reimbursed medical products (lppr) effective october 25, 2021. this was the final step to full commercial launch of cguard eps following cnedimts' positive opinion for reimbursement received by the company on may 11, 2021 for the treatment of symptomatic and non-symptomatic lesions when surgery is not indicated.
NSPR Ratings Summary
NSPR Quant Ranking